Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.
Accelerate precision oncology with Crown Bioscience’s high-quality human biospecimens—comprehensive, clinically annotated samples including tumor tissue, plasma, and PBMCs, optimized for multi-omics research and biomarker discovery.
Accelerate Drug Discovery with Crown Bioscience's Comprehensive DMPK / ADME Services
Cell Line-Derived Xenograft Models, Established multiple in vivo assay systems to evaluate novel anticancer compounds, with each assay specifically designed to understand a drug's mechanism of action, or an individual agent property.
Accelerate oncology drug development with Crown Bioscience’s PDX Mouse Clinical Trials. Leverage the world’s largest clinically relevant PDX collection to model patient tumor heterogeneity, predict clinical outcomes, discover biomarkers, and optimize drug strategies. Improve clinical translation and reduce attrition with highly predictive, patient-relevant insights.
CrownSyn™: Quantify and visualize drug synergy, antagonism, or additivity in vitro and in vivo with Crown Bioscience’s robust bioinformatics platform—empowering oncology researchers to optimize combination therapies with confidence.
Accredited biomarker testing and bioinformatics services for oncology and translational research.
Delve into biomarker discovery and drug development with Crown Bioscience’s next-generation proteomics services—leveraging 4D-DIA technology for deep, reproducible protein profiling and post-translational modification analysis.
Unlock immune insights with Crown Bioscience’s high-throughput flow cytometry—precisely characterize immune cell populations across tissues to elucidate drug mechanisms, assess pharmacodynamics, and optimize immunotherapies.
Accelerate the development of your immuno-oncology drugs with Crown Bioscience’s large panel of immunocompetent syngeneic models.
Crown Bioscience’s preclinical biomarker services help identify, validate, and analyze biomarkers across diverse in vitro and in vivo cancer models. Using multi-omics platforms and expert bioinformatics, these services support drug mechanism studies, patient stratification, and companion diagnostic development to guide oncology drug discovery.
PDX Models Empower your research with models that reflect today’s patients and treatments.
Unlock deeper insights into tissue organization and cellular interactions with Crown Bioscience’s spatial biology and digital pathology services, featuring advanced imaging, automated analysis, and high-throughput biomarker screening for applications in cancer research, immunology, and more.
Explore your translational research with Crown Bioscience’s comprehensive genomics services—offering PCR/qPCR, next-generation sequencing, and advanced bioinformatics to deliver high-quality, reproducible data for biomarker discovery and drug development.
